24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Medical Disorders
Resources
Basic InformationLookupsLatest News
For Many With Mild Asthma, Popular Rx May Not Work: StudyCleaner Air Linked to Lower Asthma Rates in KidsCholesterol Levels Improving Among U.S. KidsPool Chemicals Harm Thousands Every SummerAre Diets High in Processed Foods a Recipe for Obesity?Lupus Takes Bigger Toll on Longevity for BlacksScientists Spot Unexpected Player in FibromyalgiaAnthrax Is a Risk on Every ContinentAHA News: More Clues to the Genetics Behind an Inherited Cholesterol DisorderSuspect Your Child Has an Ear Infection? There May Soon Be an App for ThatLyme Disease Now a Threat in City Parks Health Tip: Treating a Charley HorseMore Back-to-Back Heat Waves Will Come With Climate ChangeParents, Here's How to Protect Your Child During Measles OutbreaksAHA News: Dangerous Blood Clots May Be the Latest Risk From 'Bad' CholesterolAre You Running Short on Iron?1 in 4 American Workers Struggles With Back PainInjured Lungs Can Be Regenerated for Transplant: StudyKeeping Your Summer Fun on Sound FootingMore Active Lupus Linked to Childhood EventsSigns of Rheumatoid Arthritis Can Show Up Long Before DiagnosisSummer Is Tough for Asthma SufferersHepatitis A Infections Soaring: CDCIs the County You Call Home a Potential Measles Hotspot?'Zap' Ear Clip May Ease A-FibTake Steps to Prevent a StrokeDoes Removing Your Appendix Put You at Risk for Parkinson's?Potentially Blinding Shingles of the Eye on the RisePsoriasis, Mental Ills Can Go Hand in HandAfter Concussions, Some Ex-Athletes Show Key Marker for Brain Disease: StudyWindow for Safe Use of Clot-Buster Widens for Stroke PatientsAn Antibiotic Alternative? Using a Virus to Fight BacteriaDo Adults Need a Measles Booster Shot?Military Tourniquets Might Save Kids' Lives During School ShootingsWell Water's Spillover Effect: Heart Damage?AHA News: Helping Asian-Americans Fight Their Hidden Heart RisksSunscreen Chemicals Enter Bloodstream at Potentially Unsafe Levels: Study'Ringing in the Ears' May Drive Some to the Brink of SuicideBlood Test Might Diagnose Chronic Fatigue SyndromeAsthma Inhalers Incorrectly Used by Most Kids in StudyDevice Helps Doctors Select Lungs for TransplantBenlysta Approved for Children With LupusIn a World First, Drone Delivers Kidney for TransplantHigh Measles Rates Mean Kids, Adults Need Proper Vaccination: CDCParents, Protect Your Kids as Measles Outbreaks SpreadWork Stress, Poor Sleep, High Blood Pressure a Deadly TrioFor Obese People, Commuting by Car Can Be a Killer: StudyHealth Tip: Tick RemovalHalf of Older Dialysis Patients Die Within a Year, Study FindsIs Peanut Allergy 'Immunotherapy' Causing More Harm Than Good?
Questions and AnswersLinks
Related Topics

Diabetes

Small Trial Provides New Hope Against Parkinson's Disease

HealthDay News
by -- E.J. Mundell
Updated: Mar 1st 2019

new article illustration

FRIDAY, March 1, 2019 (HealthDay News) -- It may be possible to restore brain cells damaged by Parkinson's disease and reverse a patient's condition, something no current treatment can do, according to British researchers who conducted potentially groundbreaking clinical trials.

They cautioned the trial was small -- just 41 patients -- and the research is still in its early days. But the results of the approach, which delivers special "growth factor" proteins to restore failing brain cells, are very promising.

"The spatial and relative magnitude of the improvement in the brain scans is beyond anything seen previously in trials of surgically delivered growth-factor treatments for Parkinson's," principal investigator Dr. Alan Whone said in a news release from Parkinson's UK, which helped fund the study.

"This represents some of the most compelling evidence yet that we may have a means to possibly reawaken and restore the dopamine brain cells that are gradually destroyed in Parkinson's," he said.

One Parkinson's expert in the United States was cautiously optimistic about this cellular "reawakening."

"While on some measures this biological change did not correlate with improved symptoms, on other 'secondary' goals there was indeed a highly positive effect on patients' lives," noted Dr. Michael Schulder. He is vice chair of neurosurgery at North Shore University Hospital in Manhasset, N.Y.

"This trial should be the beginning and not the end of further efforts to harness the regenerative potential of [this therapeutic approach] to cure people with Parkinson's disease," Schulder said.

In the trial, Whone and his colleagues focused on a naturally occurring protein in the brain called Glial Cell Line Derived Neurotrophic Factor (GDNF). It was thought that boosting GDNF in brain tissue might help regenerate dying brain cells in people with Parkinson's -- and thereby reverse the condition.

Of course, the human brain is sequestered from the rest of the body by a natural defense called the blood-brain barrier, so delivering GDNF to the brain poses a problem.

In the trial, the British team used robot-assisted surgery to place four tubes into the brains of six Parkinson's patients so that GDNF could bypass this barrier and be infused directly to affected brain areas.

Once the safety of the procedure was ascertained, the trial was expanded to include 35 more patients.

Half of these patients received GDNF and half received a placebo. After the first nine months, patients in both groups were then offered GDNF for a further nine months.

At the nine-month point of follow-up, trial results were mixed. While there were some encouraging signs of improvement in patients who received GDNF, there were no significant differences between them and the placebo group on any assessments of Parkinson's symptoms.

However, a comparison of brain scans conducted before the trial and then nine months after showed that GDNF did seem to be healing the damage to dopamine-producing brain cells.

Nine months after therapy, patients who received GDNF experienced a 100 percent improvement in a key area of the brain affected by Parkinson's -- suggesting the treatment was starting to reawaken and restore damaged brain cells, the researchers said.

The real change came 18 months after the treatment, when all participants had received GDNF.

At this point, both groups showed moderate to large improvements in their Parkinson's symptoms, compared to before the study.

This indicates that the treatment might indeed have long-term beneficial effects, Whone's team said.

However, Whone cautioned that at the 18-month point there was no longer a comparison group (both groups were now receiving GDNF). Also, the trial was no longer "blinded" -- meaning all of the patients now knew they were receiving GDNF. That makes it tougher to rule out a placebo effect.

Therefore, the findings at 18 months need to be viewed with caution, the researchers said.

As to why symptoms didn't seem to be affected by the therapy at nine months, "it may be that the effects on symptoms lag behind the improvement in the brain scans, so a longer double-blind trial may have produced a clearer effect," Whone suggested.

"It's also possible that a higher dose of GDNF would have been more effective, or that participants at an earlier stage of the condition would have responded better," he theorized.

"This is why it's essential to continue research exploring this treatment further -- GDNF continues to hold potential to improve the lives of people with Parkinson's," Whone added.

Schulder agreed.

"Brain imaging showed that the GDNF appeared to have brought about regeneration of the key cells whose death leads to the progressive symptoms of Parkinson's disease," he said, so further trials are warranted.

Arthur Roach directs research at Parkinson's UK. In the news release, he said that "while the results are not clear-cut, the study has still been a resounding success.

"It has advanced our understanding of the potential effects of GDNF on damaged brain cells, shown that delivering a therapy in this way is feasible and that it is possible to deliver drugs with precision to the brain," Roach said.

The results were published Feb. 26 in the journal Brain and the Journal of Parkinson's Disease.

More information

The Parkinson's Foundation has more on Parkinson's disease.